Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease (DKD) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report outlays ...

In addition to AIS, DiaMedica (DMA.V) (DMCAF) is also developing DM199 for the treatment of diabetic kidney disease (DKD). Diabetic kidney disease (DKD) or Diabetic nephropathy (DN) is one of the most ...

In a study of 70 patients with type 2 diabetes, MPO and NE mRNA expression was higher in severe albuminuric DKD and ...

A new study unveiled on day 2 of ESC Congress 2021 showed finerenone, a nonsteroidal mineralocorticoid receptor antagonist, offers benefits to patients with mild to moderate CKD and type 2 diabetes.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that detailed results from the FIDELIO-DKD Phase III study demonstrated that the investigational drug finerenone slowed the progression of ...

George L. Bakris, MD, describes the design and results of the FIDELIO-DKD trial investigating the effect of finerenone on patients with chronic kidney disease. Neil B. Minkoff, MD: Dr Bakris, I ...

Please provide your email address to receive an email when new articles are posted on . Topline findings from the FIDELIO-DKD study show the investigational drug finerenone delayed the progression of ...

In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its Phase II pipeline for diabetic kidney disease (DKD). The objective of the Phase IIb study was to evaluate the ...

Evidence of a substantial heritability of diabetic kidney disease (DKD) exists but the genetic background is poorly understood. New data confirm that renal complications in type 1 diabetes mellitus ...